利妥昔单抗联合或不联合阿伐可泮治疗伴严重肾受累的ANCA相关性血管炎
该回顾性队列研究纳入eGFR<30 ml/min/1.73 m2的ANCA相关性血管炎患者,比较利妥昔单抗联合阿伐可泮(n=30)与单用利妥昔单抗(n=120)的疗效。结果显示阿伐可泮显著减少12个月累积泼尼松暴露并缩短停药时间,但两组肾脏缓解率和eGFR轨迹无显著差异。
要点
- 阿伐可泮显著降低12个月累积泼尼松暴露(1.8 vs 4.3 g;P < 0.001)。
- 阿伐可泮缩短泼尼松停药时间(3.3 vs 7.3个月;log-rank P < 0.001)。
- 两组肾脏缓解率(HR 0.74,95%CI 0.45-1.21;P=0.232)和eGFR轨迹无显著差异。
核心结论
- 在利妥昔单抗诱导治疗的伴严重肾受累AAV患者中,阿伐可泮未改善肾脏缓解率或纵向eGFR轨迹,但显著且更快减少糖皮质激素用量,安全性可接受。
研究设计与样本
- 梅奥诊所回顾性比较队列研究,纳入2010至2025年诱导治疗时eGFR<30 ml/min/1.73 m2的AAV患者,利妥昔单抗联合阿伐可泮组n=30,单用利妥昔单抗组n=120。
主要发现
- 两组基线特征均衡,中位eGFR分别为15.0和16.0 mL/min/1.73 m2,基线需透析者分别占13.3%和12.5%。
- 阿伐可泮组12个月累积泼尼松暴露为1.8 g,单用利妥昔单抗组为4.3 g(P < 0.001)。
- 阿伐可泮组泼尼松停药时间为3.3个月,单用利妥昔单抗组为7.3个月(log-rank P < 0.001)。
- 调整后Cox回归显示肾脏缓解无显著差异(HR 0.74,95%CI 0.45-1.21;P = 0.232),纵向eGFR轨迹亦无显著差异。
- 1例(3.3%)因药物性肝损伤停用阿伐可泮,停药后转氨酶恢复正常。
关键数值与推荐
- 肾脏缓解定义为eGFR下降不超过25%且血尿≤10个红细胞/高倍视野。
临床怎么用
- 对于伴严重肾受累的AAV患者,阿伐可泮可在利妥昔单抗基础上作为减少糖皮质激素暴露的选择,但需监测肝毒性。
局限性
- 回顾性比较队列设计,样本量有限(阿伐可泮组n=30),可能存在未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Avacopan has shown efficacy as a glucocorticoid-sparing therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but its benefit in patients with severe renal involvement treated with rituximab remains uncertain. METHODS: We conducted a retrospective comparative cohort study at Mayo Clinic including patients with AAV and estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.73 m2 at induction treated with rituximab plus avacopan (n = 30) or rituximab alone (n = 120) between 2010 and 2025. Coprimary outcomes were time to renal remission (no > 25% eGFR decline and hematuria ≤ 10 red blood cells per high-power field [RBC/HPF]), analyzed by Kaplan-Meier and Cox proportional hazards regression, and longitudinal eGFR trajectory, analyzed by linear mixed-effects models. RESULTS: Baseline characteristics were well balanced. Median eGFR was 15.0 and 16.0 mL/min/1.73 m2 and dialysis was required at baseline in 13.3% and 12.5% in the avacopan and rituximab groups, respectively. Avacopan significantly reduced cumulative prednisone exposure at 12 months (1.8 vs 4.3 g; P < 0.001) and shortened time to prednisone discontinuation (3.3 vs 7.3 months; log-rank P < 0.001). On adjusted Cox regression, renal remission did not differ significantly between groups (hazard ratio [HR], 0.74, 95% confidence interval [CI], 0.45-1.21; P = 0.232). Longitudinal eGFR trajectories did not differ significantly between groups. One patient (3.3%) discontinued avacopan because of drug-induced liver injury, with transaminase normalization after discontinuation. CONCLUSIONS: In our cohort of patients with AAV and severe renal involvement treated with rituximab-based induction, avacopan did not improve renal remission rates or longitudinal eGFR trajectory in comparison to glucocorticoids but achieved significant and faster glucocorticoid reduction with an acceptable safety profile.
引用
- Juanet C, Hassi I, Cara A, et al. Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement. Kidney Int Rep. 2026. PMID: 42761229. doi:10.1016/j.ekir.2026.107009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。